Low serum EPA/arachidonic acid levels are reportedly associated with an increased risk for cardiovascular disease (13), and oral EPA has been shown to reduce cardiovascular risk and to lower both C-reactive protein (CRP) and low-density lipoprotein (LDL) levels (14, 15). Here, CRP is linked to cardiovascular disorder.